DALLAS, Oct. 2, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biotechnology company Geovax Labs Inc. (OTCBB:GOVX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Geovax Labs Inc. (OTCBB:GOVX) should be of particular interest to other biotechnology companies: Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Sanofi-Aventis (NYSE:SNY) and Merck & Co. Inc. (NYSE:MRK).
The full report is available at: http://www.stockpreacher.com/n/GOVX
Geovax Labs Inc. (GOVX) is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. The Company's goal includes: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I, II and III human trials for vaccine safety and effectiveness, and obtaining regulatory approval of these vaccines in the USA and specified international markets.
In the report, the analyst notes:
"The Company's HIV vaccine candidates have successfully completed preclinical efficacy testing in non-human primates and phase I clinical testing trials in humans. A phase IIa human clinical trial for a preventative HIV vaccine candidate was initiated during the fourth quarter 2008, and patient enrollment commenced in February 2009. The Company reported that its partner, the HIV Vaccine Trials Network (HVTN), has enrolled 30% of the projected participants. The HVTN has sponsored more than 80 phase I trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines. The results of these trials have merited only five phase II trials. Progressing to phase II is a significant step for GOVX.
"GOVX has announced that it has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration to discuss a proposed IND for therapeutic vaccine as a treatment for individuals infected with HIV/AIDS. The Company is currently in the midst of planning the details of a phase I human clinical trial and expects to begin this trial, assuming FDA approval, in the first quarter of 2010. The preventative trial, designated as HVTN 205, is being conducted by the HVTN."
To read the entire report visit: http://www.stockpreacher.com/n/GOVX
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.